Akari Therapeutics

Compare

309 Followers

AKTX Stock Chart & Stats

$0.75

-$0.09(-6.73%)

At close: Jan 08 4:00 PM EST

$0.75

-$0.09(-6.73%)

Day’s Range― - ―

52-Week Range$0.57 - $3.15

Previous CloseN/A

Volume16.29K

Average Volume (3M)353.77K

Market Cap

$25.16M

Enterprise Value$35.60M

Total Cash (Recent Filing)$2.71M

Total Debt (Recent Filing)$1.55M

Price to Earnings (P/E)―

Beta0.49

Next Earnings

Apr 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding35,737,576

10 Day Avg. Volume136,951

30 Day Avg. Volume353,772

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.41

Enterprise Value/Revenue1.37K

Enterprise Value/Gross Profit2.74K

Enterprise Value/Ebitda-2.61

Forecast

1Y Price Target

$3.30

Price Target Upside340.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Innovative Cancer TherapyAkari announced preclinical data demonstrating activity of its antibody drug conjugate (ADC) novel payload PH1 in prostate cancer, particularly in the presence of AR-V7, a splice variant of the androgen receptor that is a key driver of progression of metastatic castration resistant prostate cancer (mCRPC).

Potential For Combination TherapiesPH1 demonstrated activity as a single agent as well as a combination with ARPIs, further demonstrating its mechanism of action in blocking the spliceosome and driving direct cytotoxic effects.

Safety And Efficacy AdvantagePH1 has considerable advantages in terms of its safety/toxicity profile, immune-driven bystander effects, and potential for combinations with immune therapies like checkpoints.

Bears Say

Financial RiskThe company's weak balance sheet may present a significant risk.

Funding UncertaintyThe financial overhang may weigh on the stock until the company is able to secure additional funds.

Akari Therapeutics News

Akari Therapeutics announces formation of SAB

Akari Therapeutics (AKTX) announced the formation of its Scientific Advisory Board, SAB, and inaugural appointment of Dr. Sara...

4h ago

AKTX

Akari Therapeutics launches CEO Corner platform

Akari Therapeutics (AKTX) announced the launch of its CEO Corner featuring Abizer Gaslightwala, President and CEO of Akari....

8d ago

AKTX

Akari Therapeutics prices 3.13M ADSs at 80c in registered direct offering

Akari Therapeutics (AKTX) entered into a definitive agreement for the issuance and sale of an aggregate of 3,125,000...

15d ago

AKTX

Akari Therapeutics files two new patents with USPTO

Akari Therapeutics (AKTX) announced that it has filed two new provisional patent applications with the United States Patent...

21d ago

AKTX

Akari Therapeutics Appoints Kameel Farag as Interim CFO

The latest announcement is out from Akari Therapeutics ( ($AKTX) ). On October 22, 2025, Akari Therapeutics appointed...

7d ago

AKTX

Akari Therapeutics Announces $2.5 Million Direct Offering

Akari Therapeutics ( ($AKTX) ) has issued an announcement. On October 14, 2025, Akari Therapeutics entered into a...

14d ago

AKTX

Akari Therapeutics Announces $2.5 Million Direct Offering

An update from Akari Therapeutics ( ($AKTX) ) is now available. On October 15, 2025, Akari Therapeutics announced...

15d ago

AKTX

Akari Therapeutics Completes August 2025 Notes Offering

The latest announcement is out from Akari Therapeutics ( ($AKTX) ). Akari Therapeutics successfully completed the issuance of...

1M ago

AKTX

Akari Therapeutics Reveals Promising Preclinical Data for PH1

Akari Therapeutics ( ($AKTX) ) has shared an update. Akari Therapeutics announced a significant amendment to its convertible...

1M ago

AKTX

Innovative Cancer Treatment Approach Drives Buy Rating for Akari Therapeutics

Akari Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

1M ago

AKTX

Akari Therapeutics announces preclinical data on PH1

Akari Therapeutics (AKTX) announced key preclinical data demonstrating the potential of its novel antibody drug conjugate, ADC, spliceosome...

1M ago

AKTX

Akari Therapeutics Stock (AKTX) Rises after Filing Patent for Novel Cancer Therapy

Biotech company Akari Therapeutics’ ($AKTX) shares, which have plunged about 35% over the past three months, trended upward...

1M ago

AKTX

Akari files for patent on ADC platform using spliceosome payload PH1

Akari Therapeutics (AKTX) has filed a provisional patent application with the United States Patent and Trademark Office covering...

1M ago

AKTX

Akari Therapeutics’ Strategic Shift and Innovative ADC Platform Earns Buy Rating Despite Financial Constraints

Akari Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Lee CFA...

2M ago

AKTX

AKTX FAQ

What was Akari Therapeutics’s price range in the past 12 months?

Akari Therapeutics lowest stock price was $0.57 and its highest was $3.15 in the past 12 months.

What is Akari Therapeutics’s market cap?

Akari Therapeutics’s market cap is $25.16M.

When is Akari Therapeutics’s upcoming earnings report date?

Akari Therapeutics’s upcoming earnings report date is Apr 07, 2026 which is in 159 days.

How were Akari Therapeutics’s earnings last quarter?

Akari Therapeutics released its earnings results on Sep 25, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.03.

Is Akari Therapeutics overvalued?

According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akari Therapeutics pay dividends?

Akari Therapeutics does not currently pay dividends.

What is Akari Therapeutics’s EPS estimate?

Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Akari Therapeutics have?

Akari Therapeutics has 35,737,576 shares outstanding.

What happened to Akari Therapeutics’s price movement after its last earnings report?

Akari Therapeutics reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 0.901%.

Which hedge fund is a major shareholder of Akari Therapeutics?

Currently, no hedge funds are holding shares in AKTX

Company Description

Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics (AKTX) Earnings & Revenues

Historic Earnings Reports

AKTX Stock 12 Month Forecast

Average Price Target

$3.30

▲(340.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","17":"$17","26":"$26","35":"$35","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,8,17,26,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2021","6":"Nov<br/>2024","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.7,1.0307692307692307,1.3615384615384616,1.6923076923076923,2.023076923076923,2.3538461538461535,2.684615384615385,3.0153846153846153,3.346153846153846,3.676923076923077,4.007692307692308,4.338461538461538,4.6692307692307695,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.7,0.8999999999999999,1.0999999999999999,1.2999999999999998,1.5,1.6999999999999997,1.9,2.0999999999999996,2.3,2.5,2.6999999999999997,2.8999999999999995,3.0999999999999996,{"y":3.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.7,0.7692307692307692,0.8384615384615384,0.9076923076923077,0.9769230769230769,1.046153846153846,1.1153846153846154,1.1846153846153846,1.2538461538461538,1.323076923076923,1.3923076923076922,1.4615384615384617,1.5307692307692307,{"y":1.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34,"date":1596240000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1598918400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1617235200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1625097600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1669852800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >